laitimes

Vguan financial report | Zero Kr Technology withdrew its IPO in the United States, losing more than 900 million yuan in two years

Zhongxin Jingwei April 12, Zero Kr Technology said on the evening of the 11th that it has applied to withdraw the US IPO plan.

Vguan financial report | Zero Kr Technology withdrew its IPO in the United States, losing more than 900 million yuan in two years

Screenshot of Zero Kr Technology announcement

On June 15, 2021, Zero Kr Technology filed an IPO application with the U.S. Securities and Exchange Commission (SEC). On July 9, 2021, Zero Kr Technology announced the suspension of its IPO and the postponement of its listing plan. Subsequently, the relevant reasons and related processes have not been disclosed.

Vguan financial report | Zero Kr Technology withdrew its IPO in the United States, losing more than 900 million yuan in two years

Shareholder Structure Source: Screenshot of prospectus

According to the prospectus, in the pre-listing shareholder structure of Zero Kr Technology, Tianze Zhang held 19.7% of the shares; Ligang Luo held 2.9% of the shares; Liping Li held 3.5% of the shares; in addition, Ali Health also held 8.4% of the shares.

Vguan financial report | Zero Kr Technology withdrew its IPO in the United States, losing more than 900 million yuan in two years

Performance Data Source: Screenshot of prospectus

According to the prospectus data, in 2019, 2020 and the first quarter of 2021, the revenue of Zero Kr Technology was 499 million, 942 million and 223 million yuan, respectively, and the corresponding net losses were 434 million, 489 million and 138 million yuan, respectively.

According to the official website of Zero Kr Technology, the company relies on the self-developed AI data governance system (LinkData), Zero Kr carries out clinical recruitment, real-world research, data insight and other services based on precision life science solutions (LinkSolutions) in the field of major diseases such as tumors and rare diseases, supported by medical evidence, accelerates clinical research, empowers post-marketing development of drugs, and carries out Internet hospital diagnosis and treatment based on the digital health management platform for patients with serious diseases (LinkCare). 3. Offline service center care and innovative insurance payment and other life-cycle services to achieve accurate and personalized care and management for patients with serious diseases.

The official website also shows that its technical research and development team is composed of senior technical talents from Baidu, Ali and Tencent. (Zhongxin Jingwei APP)

Read on